|Printable version||E-mail this to a friend|
How to facilitate development of cancer treatment based on genetically modified T-cells
Watch live broadcast of expert discussion at EMA
A workshop on the scientific and regulatory challenges of innovative cancer immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and bacteria) will take place at the European Medicines Agency (EMA) on Tuesday and Wednesday, 15-16 November 2016.
You can follow a live broadcast of the workshop by clicking on the 'multimedia' tab on the event page.
The workshop, which is organised by the Agency’s Committee for Advanced Therapies(CAT), aims to facilitate dialogue between the CAT and medicine developers from industry and academia on current scientific developments, regulatory requirements for product manufacture and clinical development of these medicines.
Immunotherapy is a type of cancer treatment that mobilises the body's own defence mechanisms to fight the cancer. Immunotherapy medicines have significantly improved the therapeutic landscape for patients with certain cancers, such as lung cancer or melanoma.
T-cell based immunotherapy is an innovative approach where T-cells from a patient’s blood are genetically engineered in a laboratory to allow them to recognise cancer cells through specific receptor proteins. In the body of a patient, these so called Chimeric Antigen Receptor (CAR) T-cells can then identify and destroy cancer cells.
CAR T-cell medicines are being developed and are currently being tested in clinical trialsin a variety of cancers. However, there are still many scientific and regulatory challenges to be overcome before these innovative products can be brought to the market for the benefit of patients.
For more information please see the agenda of the workshop.
Presentations and a video recording of the event will be published after the workshop.
- Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (15-16/11/2016)
- Committee for Advanced Therapies (CAT)
- Programme of the Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (08/11/2016)
Latest News from
EFSA reinforces independence policy22/06/2017 16:16:00
The EFSA has a robust, well-balanced independence policy, its Management Board said after approving a number of new measures to further strengthen the Authority’s impartiality and protection against improper influence.
Romania, UK, Belgium & Switzerland – coordinated takedown of a Romanian THB criminal network22/06/2017 15:20:00
On 19 June, Romanian prosecutors from the Directorate for the Investigation of Organised Crime and Terrorism (DIICOT), Piteşti Territorial Service, together with judicial police officers from the organised crime fighting structures within Piteşti, Craiova, Ploiesti, Bucharest, Vâlcea and Dâmboviţa, carried out 71 house searches in Romania.
Solidarity with Italy: €1.2 billion of EU funds to support reconstruction works after the earthquakes22/06/2017 14:10:00
The EC proposes to mobilise €1.2bn under the EU Solidarity Fund, the highest sum ever mobilised in a single instalment, following the earthquakes of 2016 and 2017 in the Italian regions of Abruzzo, Lazio, Marche and Umbria.
EC forges ahead on new transparency rules for tax planning intermediaries22/06/2017 13:37:00
The EC has proposed tough new transparency rules for intermediaries - such as tax advisors, accountants, banks and lawyers - who design and promote tax planning schemes for their clients.
Antitrust: EC fines three car lighting system producers €27m in cartel settlement22/06/2017 13:15:00
The EC has fined Automotive Lighting and Hella a total of €26,744,000 for participating in an automotive lighting cartel, in breach of EU antitrust rules. Valeo was not fined as it revealed the cartel to the Commission. All companies admitted their involvement and agreed to settle.